Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1017 - 1024 of 12013 results

New Mexico Latest State to Expand Medicaid Behavioral Health Program, Add Mobile Crisis Intervention Program
February 21, 2024| Blog| Viewpoint

FTX: Forcing The Examiner Mandate in the Third Circuit
February 21, 2024| Blog| Viewpoint

Florida Permit Ruling Shows Species Law Can Disrupt Builders
February 21, 2024| News

Mintz IRA Update — Biden Administration Proposes Allowing Agencies to 'March-In' to Control Rising Drug Prices
February 21, 2024| Blog| Viewpoint

Mintz IRA Update — Removal of AMP-Cap on Medicaid Rebates Causes Insulin Price Decrease
February 21, 2024| Blog| Viewpoint

Mintz IRA Update — Second Edition: Q1 2024
February 21, 2024| Blog| Viewpoint

Mintz IRA Update — The IRA in 2024: The Medicare Drug Price Negotiation Program in Full Swing and Other Developments
February 21, 2024| Blog| Viewpoint

Mintz IRA Update — Legal Challenges to the Medicare Drug Price Negotiation Program Continue
February 21, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
